Indivior declares a special dividend per Indivior stock
Published on 10/07/2026 at 07:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior stock (ISIN US45579U1097) is tied to a USD 8.13 special dividend declared on September 17, 2026. MarketScreener reports that the payment depends on completion of the proposed Supernus Pharmaceuticals merger.
Dividend depends on merger
The special dividend is payable on November 6, 2026, to shareholders of record on October 30, 2026. The dates give the transaction a defined cash component, while the merger condition keeps the payment linked to deal completion.
The dividend follows Indivior's second-quarter report and raised full-year outlook. The latest transaction terms therefore matter alongside operating growth, rather than replacing it.
Revenue growth sets the test
In the second quarter of 2026, revenue rose 14.00 percent year over year to USD 343.0 million, while adjusted EBITDA more than doubled to USD 186.0 million, according to IPO Grid.
For the first half of 2026, revenue reached USD 660.0 million and adjusted EBITDA reached USD 350.0 million. The company also raised its 2026 guidance to USD 1.295 billion to USD 1.365 billion of revenue and USD 700.0 million to USD 740.0 million of adjusted EBITDA, according to IPO Grid.
Nasdaq valuation remains wide
Indivior was last at USD 35.90 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. Its 52-week range was USD 22.78 to USD 42.81, leaving a USD 7.10 gap between the latest primary-exchange price and the yearly high.
The market capitalization stood at USD 4.5 billion on October 6, 2026. The latest Lang & Schwarz data set shows a prior close of EUR 31.90 on October 5, 2026.
The further course of trading is shown by the continuously updated real-time quote of Indivior stock.
Indivior stock facts
- Company: Indivior Pharmaceuticals, Inc.
- ISIN: US45579U1097
- Ticker: INDV
- Primary exchange: Nasdaq
- Prior close Lang & Schwarz (October 5, 2026): EUR 31.90
- Market capitalization: USD 4.5 billion (as of October 6, 2026)
- 52-week range: USD 22.78-USD 42.81 (as of October 6, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
